Use of biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: Evaluation of suitable purification process conditions

被引:9
作者
Bedu-Addo, FK
Johnson, C
Jeyarajah, S
Henderson, I
Advant, SJ [1 ]
机构
[1] Diosynth RTP Inc, Cary, NC 27513 USA
[2] Dynport Vaccine Co LLC, Frederick, MD 21702 USA
关键词
botulinum neurotoxin; circular dichroism; differential scanning calorimetry; proteins; purification;
D O I
10.1023/B:PHAM.0000036908.70139.f1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to investigate the physicochemical and structural characteristics of recombinant botulinum serotype B (rBoNTB(Hc)) under various conditions and to use the information in evaluating suitable purification process conditions. Methods. The solubility of rBoNTB( Hc) was evaluated at pH 4, 5, 6 7.5, 8, and 9. Secondary structure was evaluated using circular dichroism, and conformational stability was monitored using high-sensitivity differential scanning calorimetry. Hydrophobic interaction chromatography, size exclusion chromatography-high performance liquid chromatography (SEC-HPLC), sodium dodecyl sulfate-poly acrylamide gel electrophoresis (SDS-PAGE), peptide mapping, and UV spectroscopy were used to monitor stability under the various conditions. Results. The secondary structure of rBoNTB( Hc) consists predominantly of beta-sheets. Solubility of rBoNTB( Hc) was lowest at its pI and highest at low and high pH. In the presence of NaCl, however, solubility decreased with increase in pH. Conformational and chemical stability are improved below pH 7.5. In the presence of 150 mM NaCl at high pH, conformational and chemical stability of rBoNTB( Hc) are further decreased. The study suggests that the purification process should minimize exposure of rBoNTB( Hc) to high pH and salt conditions. Conclusions. Optimal stability of rBoNTB( Hc) is achieved at low pH. The biophysical and analytical studies provide us with an understanding of rBoNTB( Hc) stability behavior in solution and assists in developing efficient purification conditions.
引用
收藏
页码:1353 / 1361
页数:9
相关论文
共 27 条
[1]  
ANDERSON JH, 1981, BIOMEDICAL ASPECTS B, P233
[2]  
[Anonymous], 1989, BOTULINUM NEUROTOXIN
[3]  
BANDYOPADHYAY S, 1987, J BIOL CHEM, V262, P2660
[4]   Identifying the principal protective antigenic determinants of type A botulinum neurotoxin [J].
Bavari, S ;
Pless, DD ;
Torres, ER ;
Lebeda, FJ ;
Olson, MA .
VACCINE, 1998, 16 (19) :1850-1856
[5]  
Bedu-Addo F, 2002, AAPS PHARMSCI, V4
[6]   Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate [J].
Byrne, MP ;
Smith, TJ ;
Montgomery, VA ;
Smith, LA .
INFECTION AND IMMUNITY, 1998, 66 (10) :4817-4822
[7]   PROTECTIVE VACCINATION WITH A RECOMBINANT FRAGMENT OF CLOSTRIDIUM-BOTULINUM NEUROTOXIN SEROTYPE A EXPRESSED FROM A SYNTHETIC GENE IN ESCHERICHIA-COLI [J].
CLAYTON, MA ;
CLAYTON, JM ;
BROWN, DR ;
MIDDLEBROOK, JL .
INFECTION AND IMMUNITY, 1995, 63 (07) :2738-2742
[8]  
DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53
[9]   Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum [J].
Dertzbaugh, MT ;
West, MW .
VACCINE, 1996, 14 (16) :1538-1544
[10]   Induction of an immune response by oral administration of recombinant botulinum toxin [J].
Kiyatkin, N ;
Maksymowych, AB ;
Simpson, LL .
INFECTION AND IMMUNITY, 1997, 65 (11) :4586-4591